# Normunity

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/normunity

- Industry: Biotechnology
- Headquarters: West Haven, US
- Website: www.normunity.com
- Total disclosed funding: $140M
- Latest round: Series B (Jan 14, 2025)
- Investors on record: 12

## About

Based in Connecticut, US, and founded in 2021 by CEO Rachel Humphrey, and Lieping Chen, Normunity Inc., a.k.a. Normunity is a biotech company that develops a new class of precision immuno-oncology medicines that target novel mechanisms that free the body’s normal immunity against cancer. n January 2025, Normunity Inc. raised USD 75 million in series B funding co-led by Samsara BioCapital and Enavate Sciences, with participation from returning investors Canaan Partners, Sanofi Ventures, Taiho Ventures, Osage Venture Partners, HongShan Capital Group, and Connecticut Innovations. New investors Regeneron Ventures, Pfizer Venture Investments, and YK Bioventures also participated in the round.


The company provides a pipeline of immune normalizers that can restore the immune system’s intrinsic activity to identify and eliminate cancer cells. Normunity is also developing immunotherapies that will be precision cancer medicines developed with companion diagnostics for treating cancer as monotherapy and in combinations. The firm’s lead program is a monoclonal antibody that targets a secreted enzyme that is highly upregulated in multiple human cancers and drives the exclusion of T-cell infiltration in immuno-sensitive tumors. In addition, Normunity is advancing additional immune normalizer programs that target other mechanisms of immune cell exclusion and other mechanisms outside the tumor microenvironment that attenuate immune function.

The company plans to use the January 2025 funding to advance its lead drug program, NRM-823, into clinical trials, and broaden its pipeline of novel anti-cancer therapies targeting untapped drug mechanisms.

## Funding rounds

- Series B, Jan 14, 2025, $75M — Canaan Partners, Connecticut Innovations, Pfizer Venture Investments, Sanofi Ventures, Taiho Ventures, Samsara BioCapital, HSG, Osage Venture Partners, Enavate Sciences, YK Bioventures, Regeneron Ventures
- Series A, Oct 25, 2022, $65M — OUP (Osage University Partners), Sanofi Ventures, Taiho Ventures, Canaan Partners

## Investors

- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series A, Series B
- Taiho Ventures (https://capitalatlas.ai/funds/taiho-ventures) — Series A, Series B
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B
- Connecticut Innovations (https://capitalatlas.ai/funds/connecticut-innovations) — Series B
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B
- HSG (https://capitalatlas.ai/funds/hsg) — Series B
- Osage Venture Partners (https://capitalatlas.ai/funds/osage-venture-partners) — Series B
- Enavate Sciences — Series B
- YK Bioventures (https://capitalatlas.ai/funds/yk-bioventures) — Series B
- Regeneron Ventures (https://capitalatlas.ai/funds/regeneron-ventures) — Series B